Oryzon Genomics, a biopharmaceutical company of clinical phase focused on epigenetics for the development of therapies for diseases with important unresolved medical needs, today announced the results of the vote of the extraordinary general meeting of shareholders held in Madrid. A total of 24,030,812 of the ordinary shares issued and in circulation of the company (which represent 36,5312% of the share capital) were represented at the Board, whether in person or by delegation.
The shareholders of the company approved all the agreements listed below, proposed by the Board of Directors at the Extraordinary General Meeting of the Company, with favorable votes that ranged between 94% and 97%.
- Appointment and re -election of directors.
- Reelection of D. Carlos Buesa as counselor with the executive qualification.
- Reelection of Mr. Manuel López-Figueroa as a counselor with the independent qualification.
- Appointment of D. Konstantinos Allatis as a counselor with the independent qualification.
- Appointment of Mr. Luis Sánchez Quintana as a counselor with the independent qualification.
- Appointment of Mrs. Montserrat Vendrell as counselor with the independent qualification.
- Appointment of D. Pierre Beaurang as counselor with the independent qualification.
- Approval of the issuance of obligations convertible into actions, excluding the preferential subscription right, under the financing agreement signed with Nice & Green, SA, dated November 20, 2023.
- Delegation in the Board of Directors, of the power to increase the share capital in the terms of article 297.1.b) of the Capital Companies Law. Delegation for the exclusion of the preferential subscription right in accordance with the provisions of article 506 of the Capital Companies Law.
- Delegation in the Board of Directors of the Faculty to issue fixed income values, preferential participations or Nature Analog Instruments (including promissory notes or warrants) and/or exchangeable in society actions. Fixing criteria for the determination of the bases and modalities of conversion and/or exchange and attribution to the Board of Directors of the powers to increase capital in the necessary amount, as well as excluding the right of preferential subscription of the shareholders and holders of convertible values.
- Authorization to the Board of Directors for the acquisition of own actions, directly or, where appropriate, through company -dependent societies.
- Delegation of powers for the formalization, correction, registration, interpretation, development and execution of the agreements adopted by the General Meeting.
The complete detail of the proposals of agreement that have been approved in its entirety and the result of the voting by independent points can be consulted on the website of the company soon.